High-Throughput Drug Screening Identifies EGFR/MAPK Pathway Targeting Sensitivities in Organoid Models of Ovarian Carcinosarcoma

Researchers carried out drug screens in the presence of cisplatin or eribulin to identify synergistic combinations. They validated the top combinations in their unique ovarian carcinosarcoma cell line, organoid, and patient-derived xenograph models.